RGNX

Regenxbio

• PR Newswire·1d ago

  RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

• Reuters·04/03 20:31

  Regenxbio announces annual shareholder meeting, releases preliminary proxy statement

• PR Newswire·04/03 20:31

  RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

• PR Newswire·04/03 19:19

  REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights

• PR Newswire·04/01 13:00

  STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP

• PR Newswire·03/30 08:18

  RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

• PR Newswire·03/30 08:02

  RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

• Reuters·03/26 13:04

  Regenxbio shares drop 17.8% due to RGX-111 securities class action; lead plaintiff deadline set for April 14, 2026

• PR Newswire·03/26 13:00

  SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

• Benzinga·03/26 12:30

  FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease

• PR Newswire·03/24 22:36

  RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

• TipRanks·03/24 15:47

  Shareholders Sue RGNX Over Gene Therapy Study Claims

• TipRanks·03/24 10:17

  Bank of America Securities Keeps Their Buy Rating on RegenXBio (RGNX)

• Benzinga·03/20 21:34

  Regenxbio Enters Settlement And Release Agreement With GlaxoSmithKline On March 18, 2026; To Pay $10.0M To GlaxoSmithKline For Alleged Underpayment Of Sublicense Fees; Settlement Agreement Includes Mutual Releases Of Past And Certain Future Claims; To Continue To Pay GSK Amounts Received From Sublicensees Pursuant To Existing Sublicense Agreements

• TipRanks·03/20 21:28

  RegenXBio Reaches Settlement with GSK Over License Fees